Cargando…
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
BACKGROUND: An increasing proportion of patients are exposed to anthracyclines and/or taxanes in the adjuvant or neoadjuvant setting. Re-exposure in the metastatic stage is limited by drug resistance, thus evaluation of non-cross-resistant regimens is mandatory. METHODS: Anthracycline-pretreated pat...
Autores principales: | Stemmler, H J, diGioia, D, Freier, W, Tessen, H W, Gitsch, G, Jonat, W, Brugger, W, Kettner, E, Abenhardt, W, Tesch, H, Hurtz, H J, Rösel, S, Brudler, O, Heinemann, V |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068513/ https://www.ncbi.nlm.nih.gov/pubmed/21407218 http://dx.doi.org/10.1038/bjc.2011.86 |
Ejemplares similares
-
Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021) -
Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
por: Zhu, Zhou, et al.
Publicado: (2023) -
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018) -
Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020) -
Real-world outcomes of adjuvant gemcitabine versus
gemcitabine plus capecitabine for resected pancreatic ductal
adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)